Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dose-dense sequential chemotherapy with or without paclitaxel for high-risk operable breast cancer
ACTRN12611000506998Phase 3Completed
- Sponsor
- HeCOG
- Start
- Jun 1997
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of epirubicin, paclitaxel, cyclophosphamide, methotrexate and fluorouracil in breast cancer (2 arms), sponsored by HeCOG. Primary endpoint: Disease-free survival. Started Jun 1997; status: completed.
02
Drugs
epirubicinpaclitaxelcyclophosphamidemethotrexatefluorouracil
03
Conditions
breast cancer
Beyond the preview
Go deeper on ACTRN12611000506998.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12611000506998.